Guardant Health, Inc, a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX),...
Naveris, Inc., a leader in molecular diagnostics for viral cancers, announced the launch of the DART 2.0 prospective clinical trial (NCT05541016) by Mayo Clinic.
The...
